Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anteris Technologies ( (AU:AVR) ) has shared an announcement.
Anteris Technologies has announced a private placement of approximately A$38.5 million to fund its PARADIGM Trial and accelerate global commercialization efforts. The funds will support clinical strategy execution, including the pivotal DurAVR Transcatheter Heart Valve trial, manufacturing expansion, and research and development. The company aims to expand its trial globally, with regulatory clearance in Denmark and anticipated FDA approval in the U.S., enhancing its industry positioning and operational capabilities.
The most recent analyst rating on (AU:AVR) stock is a Buy with a A$10.00 price target. To see the full list of analyst forecasts on Anteris Technologies stock, see the AU:AVR Stock Forecast page.
More about Anteris Technologies
Anteris Technologies Global Corp. operates in the medical technology industry, focusing on the development and commercialization of advanced cardiovascular solutions. The company is primarily involved in creating transcatheter heart valve technologies, with a market focus on addressing aortic stenosis through innovative clinical trials and product development.
Average Trading Volume: 16,088
Technical Sentiment Signal: Sell
Learn more about AVR stock on TipRanks’ Stock Analysis page.